Trelagliptin: First Global Approval

Drugs

Volumn 75, Issue 10, 2015, Pages 1161-1164

  McKeage, Kate ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; TRELAGLIPTIN; ANTIDIABETIC AGENT; URACIL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DIET THERAPY; DRUG APPROVAL; DRUG CLEARANCE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; ELIMINATION HALF-LIFE; HUMAN; HYPOGLYCEMIA; IC50; IN VITRO STUDY; JAPAN; KINESIOTHERAPY; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; URACIL;

EID: 84937734450     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0431-9     Document Type: Article

References (9)

1. Takeda. Zafatek (trelagliptin): Japanese prescribing information. 2015. http://www.takedamed.com/content/medicine/pdf/zafatek.pdf. Accessed 27 May 2015.
2. Inzucchi SE, Bergenstal R, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429-42.
3. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-24.
4. Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989-95.
5. PPD Inc. Takeda aquires the rights to DPP4 inhibitors granted to PPD [media release]. 13 July 2005. www.ppdi.com.
6. Actavis Inc. Actavis completes acquisition of Furiex Pharmaceuticals [media release]. 2 July 2014. www.actavis.com.
7. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24-32.
8. Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:125-32.
9. Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol. 2015;3:191-7.